QTM BioSciences has developed a proprietary, label-free platform that quantifies how much of a drug actually reaches its intracellular target - a critical measurement gap in drug development. Current technologies cannot reliably measure intracellular exposure, making it difficult for developers to know whether promising compounds truly reach their site of action

QTM applies its platform across multiple cell lines and therapeutic modalities, including ADCs, small molecules, and lipid nanoparticles (LNPs), and is expanding into peptides and oligonucleotides. By providing quantitative intracellular exposure measurements that were previously inaccessible, QTM gives pharmaceutical companies with actionable mechanistic insights to improve candidate selection and translational confidence.

Founded in May 2023 and based at Pivot Park in the Netherlands, QTM has already generated over €500k, operates with a team of four and works with six major pharmaceutical companies. The company is now scaling and automating its platform to meet growing industry demand and accelerate drug development pipelines.